Merck & Company News - August 19, 2026
🟢 Merck is trading 10% up today after positive Phase 3 melanoma vaccine results
Merck is trading 10.44% up now at $149.42 after Merck and Moderna announced positive Phase 3 INTerpath-001 results for intismeran combined with Keytruda. -...
🟢 Merck is trading 12% up today after positive Phase 3 melanoma vaccine results
Merck is trading at $151.09 (+11.74%) after Merck and Moderna reported positive Phase 3 results for personalized mRNA cancer vaccine intismeran combined with...
Merck's mRNA Cancer Vaccine Breakthrough Sends Shares Surging — But Can a Personalized Shot Offset a $32 Billion Patent Cliff?
Shares of Merck vaulted 10% to $148.64 Wednesday morning after the pharma giant and partner Moderna reported that their personalized mRNA cancer vaccine hit...
🟢 Merck is trading 9.39% up today after positive Phase 3 personalized mRNA melanoma vaccine results
Merck is trading 9.39% up at $148.64 after Merck and Moderna announced positive Phase 3 results for their personalized mRNA melanoma vaccine. - Combined with...
Merck Slams Germany’s New Drug Rebates, Citing Stifled Domestic Investment
The German government approved new healthcare spending controls on August 18, 2026. These measures aim to save billions of euros by increasing mandatory...